Literature DB >> 2743263

Chromosome studies in thyroid neoplasia.

L Bondeson1, A Bengtsson, A G Bondeson, R Dahlenfors, L Grimelius, B Wedell, J Mark.   

Abstract

Cytogenetic studies in thyroid neoplasia were performed by G-banding of chromosome preparations obtained from the in vitro cultures of nine adenomas, one follicular carcinoma, five papillary carcinomas, and two medullary carcinomas. Complex structural chromosome aberrations were found in one adenoma. Two more adenomas, both composed of Hürthle cells, showed multiple numerical chromosome deviations with trisomy 4 and tetrasomy 7 in common. Six metastasizing carcinomas were characterized by normal stemlines, which indicates that malignancy in thyroid neoplasia cannot be excluded by cytogenetic techniques used currently. Comparisons between cytogenetic findings and cytophotometric DNA measurements in the material studied illustrate that euploid tumors represent a heterogenous group including cases with various gross structural chromosome aberrations of yet unknown clinical significance. Further studies of additional material with long-term follow-up are called for by our findings of structural and numerical chromosome aberrations in follicular neoplasms that are benign according to histologic criteria.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743263     DOI: 10.1002/1097-0142(19890801)64:3<680::aid-cncr2820640319>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  The study of endocrine tumors by flow and image cytometry.

Authors:  Ingrid Zbieranowski; David Murray
Journal:  Endocr Pathol       Date:  1992-06       Impact factor: 3.943

2.  DNA copy number changes in thyroid carcinoma.

Authors:  S Hemmer; V M Wasenius; S Knuutila; K Franssila; H Joensuu
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

3.  Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers.

Authors:  M A Herrmann; I D Hay; D H Bartelt; S R Ritland; R J Dahl; C S Grant; R B Jenkins
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

4.  Special features of childhood and juvenile thyroid carcinomas.

Authors:  G Balázs; G Lukács; F Juhász; F Györy; E Oláh; E Balogh
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  The morphometric analysis of cell nuclei from fine needle aspirates of thyroid follicular lesions does not improve the diagnostic accuracy of traditional cytologic examination.

Authors:  G L La Rosa; V Cavallari; D Giuffrida; S Scimone; G A La Porta; M C Maiorana; A Maiorana; A Belfiore
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

6.  A characteristic sequence of trisomies starting with trisomy 7 in benign thyroid tumors.

Authors:  G Belge; B Thode; V Rippe; S Bartnitzke; J Bullerdiek
Journal:  Hum Genet       Date:  1994-08       Impact factor: 4.132

7.  Genetic and biological subgroups of low-stage follicular thyroid cancer.

Authors:  Christopher A French; Erik K Alexander; Edmund S Cibas; Vania Nose; Julia Laguette; William Faquin; Jeff Garber; Francis Moore; Jonathan A Fletcher; P Reed Larsen; Todd G Kroll
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

8.  Loss of heterozygosity on chromosome 1p in thyroid adenoma and medullary carcinoma, but not in papillary carcinoma.

Authors:  K Kubo; K Yoshimoto; Y Yokogoshi; M Tsuyuguchi; S Saito
Journal:  Jpn J Cancer Res       Date:  1991-10

9.  Comparison of benign and malignant follicular thyroid tumours by comparative genomic hybridization.

Authors:  S Hemmer; V M Wasenius; S Knuutila; H Joensuu; K Franssila
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

10.  Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.

Authors:  I Yana; T Nakamura; E Shin; K Karakawa; H Kurahashi; Y Kurita; T Kobayashi; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.